Moderna and Merck's Personalized mRNA Vaccine Succeeds in Phase 3 Melanoma Trial
Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine (mRNA-4157/V940) combined with Keytruda in over 1,100 high-risk melanoma patients. The combination significantly extended recurrence-free and distant metastasis-free survival versus Keytruda alone, marking the first successful Phase 3 trial for a personalized mRNA cancer therapy. Moderna’s stock surged over 100%, and the companies plan to seek regulatory approval and expand trials to other cancers.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection
Cross-source coverage
Wire timeline
Merck's Personalized Cancer Vaccine Succeeds in Phase 3 Melanoma Trial, Stock Surges
On August 19, 2026, Merck and Moderna announced that their personalized mRNA cancer vaccine, Intismeran, combined with Keytruda, met primary endpoints in a Phase 3 melanoma trial (INTerpath-001). The combination significantly improved recurrence-free survival and distant metastasis-free survival in 1,137 high-risk melanoma patients compared to Keytruda alone. This is the first positive Phase 3 result for an individualized mRNA cancer therapy. Merck's stock surged 12.5%, adding roughly $43 billion in market value, as investors saw the technology validated beyond melanoma. The vaccine is strategically critical for Merck, which faces a revenue cliff in 2028 when Keytruda loses U.S. patent protection. Intismeran, being personalized and hard to copy, offers a long-term revenue replacement. Goldman Sachs estimates peak global sales for melanoma at $4.3 billion annually, with profits split 50/50 between Merck and Moderna.
Moderna Stock Surges 179% on Promising Melanoma Therapy Trial Results
Moderna Inc. (NASDAQ:MRNA) saw its share price surge up to 179% during the week of August 22, 2026, reaching a record high of $176.66, after reporting positive late-stage clinical trial results for its melanoma therapy candidate intismeran autogene, developed in partnership with Merck. The mRNA-based individualized neoantigen therapy, combined with Merck's Keytruda, met primary endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected stage IIB-IV cutaneous melanoma. This marks the first positive phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy. The combined therapy has a large addressable market, with 112,000 new melanoma cases expected in the US by year-end. Hedge funds have increased their positions in Moderna, with 52 funds holding $1.4 billion in the stock, up 49.6% from the previous quarter.
It now seems possible to vaccinate against cancer
The article reports on a significant breakthrough in cancer vaccine research, specifically the success of a trial for intismeran, an mRNA vaccine for melanoma developed by Moderna and Merck. Headlines from August 19th, 2026, hailed the results as a major step, with Moderna's shares more than doubling. The vaccine aims to prevent cancer recurrence. While the results are promising, the article questions whether this is a one-off success or the beginning of a broader new approach to treating various cancers. The tone is cautiously optimistic, noting the need for further validation.
Show 17 older updatesHide older updates
It now seems possible to vaccinate against cancer
The Economist reports on promising but not yet definitive results from a trial of intismeran, an mRNA-based vaccine for melanoma (skin cancer), announced on August 19, 2026. Headlines from other outlets hailed a breakthrough, with Moderna and Merck shares surging. The article questions whether this is a one-off success or the beginning of a new era in cancer treatment. The publication date is August 21, 2026.
It Now Seems Possible to Vaccinate Against Cancer
The Economist reports on promising but not yet definitive results from a trial of intismeran, an mRNA vaccine for melanoma developed by Moderna and Merck. Headlines on August 19th hailed a breakthrough, with Moderna's shares more than doubling on the news. The vaccine aims to stop cancer from returning after treatment. While the results are encouraging, the article questions whether this is a one-off success or the beginning of a new era in cancer treatment. The piece is part of the Science & technology section, published on August 21st, 2026.
mRNA cancer drug shows breakthrough results in large melanoma trial
U.S. drugmakers Merck and Moderna announced that their personalized mRNA-based cancer treatment, 'intismeran autogene,' successfully reduced melanoma recurrence in a late-stage clinical trial involving 1,137 patients. This marks the first time an mRNA cancer therapy has shown positive results in a large, randomized Phase 3 trial. The treatment works by analyzing a patient's tumor mutational signature and using mRNA technology to train the immune system. Patients received either the new drug plus pembrolizumab (standard of care) or pembrolizumab alone. Experts, including oncologists from Oxford and Barts Cancer Institute, hailed the results as a breakthrough and proof of principle for personalized cancer vaccines. Moderna's stock surged 145% and Merck's rose 12% on the news. The companies plan to present full data at an upcoming conference and begin regulatory filings.
Personalized mRNA Vaccine Shows Promise in Final-Stage Melanoma Trial
Moderna and Merck announced early results from a Phase 3 trial of a personalized mRNA vaccine for melanoma, combined with the immunotherapy drug Keytruda. The vaccine, tailored to each patient's tumor mutations, significantly extended the time patients remained cancer-free after surgery. While full data has not been peer-reviewed, experts call it a breakthrough and a pivotal moment for personalized cancer treatment. The companies are already testing similar vaccines for bladder, kidney, and lung cancers. The announcement caused Moderna's shares to surge, though analysts urge caution until complete data is released at a medical conference in October.
Personalized mRNA Cancer Vaccine Shows Promise in Late-Stage Melanoma Trial
Early results from a Phase 3 trial of a personalized mRNA cancer vaccine, developed by Moderna and Merck, show significant improvements in survival times for melanoma patients when combined with the immunotherapy drug Keytruda. The vaccine is tailored to each patient's tumor mutations using mRNA technology. While full data has not been peer-reviewed or publicly released, experts call it a breakthrough and a pivotal moment for cancer research. The companies are also testing similar vaccines for bladder, kidney, and lung cancers. The trial involved 1,137 high-risk melanoma patients, and further findings will be presented at a medical conference in October.
Personalized mRNA Vaccine Shows Promise in Melanoma Trial
Moderna and Merck announced early results from a Phase 3 trial of a personalized mRNA vaccine for melanoma, combined with the immunotherapy drug Keytruda. The vaccine, tailored to each patient's tumor mutations, significantly increased the time patients remained cancer-free. While full data has not been peer-reviewed, experts call it a breakthrough and a pivotal moment for personalized cancer treatment. The companies are also testing similar vaccines for bladder, kidney, and lung cancers. The trial involved 1,137 high-risk melanoma patients. Shares of both companies surged on the news.
Moderna's Melanoma Trial Success Drives Record Stock Surge and Short Seller Losses
Moderna (MRNA) closed at $174.38, up 177% in a single session, after announcing positive Phase 3 INTerpath-001 trial results for its individualized cancer therapy intismeran autogene developed with Merck. The trial met both endpoints for recurrence-free and distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma. The stock surge reflects the market's prior pricing of inconclusive outcomes, as Moderna had not disclosed statistical powering or early interim thresholds. Short sellers suffered a record single-session loss. Despite the positive data, Moderna's trailing twelve-month revenue is $2.21 billion, down 27.7% year-over-year, with an operating margin of -150.2%. Manufacturing readiness is estimated for 2027. The article notes the result validates mRNA-based therapeutic cancer vaccines but emphasizes the valuation question remains, with a market capitalization of about $69.4 billion resting on a shrinking revenue base and future growth assumptions.
Moderna Plunges 20% One Day After Cancer Vaccine Breakthrough Sent Shares Up 177%
Moderna (MRNA) shares crashed 20% on Thursday, August 20, 2026, one day after surging 177% on news that its mRNA cancer vaccine (intismeran autogene, mRNA-4157) combined with Merck's Keytruda met key Phase 3 goals in a trial for high-risk melanoma patients. The Phase 2b data showed a 49% reduction in recurrence or death versus Keytruda alone. Merck shares rose 12.5% on Wednesday. The sharp Thursday decline is attributed to profit-taking and investor reassessment of the vaccine's commercial impact. Moderna has nine Phase 2 and Phase 3 studies underway across melanoma, NSCLC, bladder cancer, and renal cell carcinoma. The vaccine is an individualized neoantigen therapy. Moderna's stock is up 369% year-to-date despite the drop.
Moderna Plunges 20% One Day After Cancer Vaccine Breakthrough Sent Shares Up 177%
Moderna (MRNA) shares crashed 20% on Thursday, August 20, 2026, one day after surging 177% following positive Phase 3 trial results for its mRNA cancer vaccine (intismeran autogene) in combination with Merck's Keytruda for high-risk melanoma. The vaccine showed a 49% reduction in recurrence or death versus Keytruda alone in a Phase 2b study. Merck shares also rose 12.5% on Wednesday. The sharp decline on Thursday is attributed to profit-taking and investor reassessment of the vaccine's commercial impact. Moderna had previously faced headwinds including a $950 million litigation settlement and a failed norovirus program. Nine Phase 2 and Phase 3 studies are now underway across multiple cancer types, including melanoma, NSCLC, bladder cancer, and renal cell carcinoma.
Merck and Moderna Achieve Breakthrough in mRNA Cancer Vaccine for Melanoma
On August 20, 2026, German news outlet Die Welt reported that pharmaceutical companies Merck and Moderna have achieved a breakthrough in developing an mRNA vaccine against melanoma, a serious form of skin cancer. The combination therapy is designed to prevent relapses and the spread of the disease. This development marks a significant advancement in cancer treatment, leveraging mRNA technology similar to that used in COVID-19 vaccines. The report highlights the potential of this therapy to improve outcomes for melanoma patients by reducing recurrence and metastasis.
Moderna and Merck report successful late-stage trial of mRNA skin cancer vaccine
Moderna and Merck announced on Wednesday that their experimental mRNA cancer vaccine, intismeran, combined with Merck's immunotherapy drug Keytruda, successfully reduced the recurrence of melanoma and prevented the deadly skin cancer from spreading to other organs in a large late-stage trial involving 1,137 high-risk patients. The results mark the first successful late-stage trial for a personalized mRNA cancer therapy, validating decades of research and paving the way for a potentially new life-extending treatment. An earlier mid-stage trial showed the combination reduced the risk of melanoma recurrence or death by 49% compared to Keytruda alone. Moderna's stock closed up 177% on the news. The companies plan to present detailed results at an international medical meeting and to regulators, with investors and researchers closely watching the vaccine's effectiveness and tolerability.
Moderna and Merck announce successful late-stage trial of mRNA skin cancer vaccine
Moderna and Merck announced on Wednesday that their experimental mRNA cancer vaccine, combined with Merck's immunotherapy drug Keytruda, successfully reduced the recurrence of melanoma in a large late-stage trial involving 1,137 high-risk patients. The personalized vaccine, called intismeran, is made by analyzing mutations in patients' own tumors. An earlier mid-stage trial showed the combination reduced the risk of melanoma recurrence or death by 49% compared to Keytruda alone. The results mark the first successful late-stage trial for a personalized mRNA cancer therapy, validating decades of research and paving the way for a potentially new life-extending treatment. The companies plan to present detailed results at an international medical meeting and to regulators. Moderna's stock closed up 177% on the news.
Moderna and Merck announce successful late-stage trial of mRNA skin cancer vaccine
Moderna and Merck announced on Wednesday that their experimental mRNA cancer vaccine, intismeran, combined with Merck's immunotherapy drug Keytruda, successfully reduced the recurrence of melanoma in a large late-stage trial involving 1,137 high-risk patients. The treatment is personalized, using genetic sequencing of patients' own tumors to create a made-to-order vaccine. An earlier mid-stage trial showed a 49% reduction in the risk of melanoma recurrence or death compared to Keytruda alone. The companies plan to present detailed results at an international medical meeting and to regulators. The Wall Street Journal called it the first successful late-stage trial for a personalized mRNA cancer therapy, validating decades of research and paving the way for a potential new life-extending treatment for melanoma and other cancers. Moderna's stock closed up 177% on the news.
Moderna's Cancer Vaccine Success Restores Wall Street Confidence
Moderna and Merck announced that their individualized cancer vaccine, intismeran, succeeded in a Phase 3 trial for melanoma, marking a major milestone after years of declining investor confidence. The vaccine, designed to target 34 unique neoantigens on tumors, was tested alongside Keytruda in an adjuvant setting. While specific data were not disclosed, the results suggest intismeran could become a multibillion-dollar treatment and potentially work against other cancers. Moderna's stock surged over 170%, adding nearly $45 billion in market value, and shares of Merck and BioNTech also rose. Analysts expressed optimism, with some projecting peak annual sales of $5.4 billion for Moderna from its 50-50 revenue split with Merck. However, some cautioned that the market's euphoric response may have overestimated the vaccine's actual sales potential and therapeutic impact.
Merck and Moderna Report Positive Melanoma Trial Results
Moderna and Merck announced that their collaborative cancer therapy, combining Merck's Keytruda antibody with Moderna's personalized mRNA immunotherapy, met its primary endpoint of improvement in recurrence-free survival and a secondary endpoint of distant metastasis-free survival in a melanoma trial. The approach tailors mRNA injections to each patient's specific tumor neoantigens using biopsy and blood samples. This was the first prespecified interim readout, and the trial will continue to evaluate overall survival. The results mark a significant step in personalized cancer treatment.
After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next
Moderna shares surged 177% on August 19, 2026, after announcing a breakthrough in a Phase 3 trial for its personalized mRNA cancer vaccine intismeran, developed with Merck. The vaccine, combined with Keytruda, significantly reduced melanoma recurrence in patients. The stock fell 12% in premarket trading the next day as analysts weighed in. Jefferies called it a proof point for mRNA beyond COVID. Bank of America saw a watershed moment for Moderna's diversification. Citigroup noted validation depends on full data and cross-tumor efficacy. JPMorgan said the launch is key to profitability but the indication is small and success may already be priced in. The full dataset is expected at ESMO in October 2026.
After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next
Moderna shares surged 177% after announcing a Phase 3 trial success for its personalized mRNA cancer vaccine intismeran, used in combination with Merck's Keytruda, which significantly reduced melanoma recurrence. The stock then fell 20% in early trading the next day as investors took profits. Wall Street analysts offered mixed reactions: Jefferies called it a key proof point for mRNA beyond COVID; Bank of America saw a watershed moment for Moderna's diversification; Citigroup noted the need for full data and cross-tumor validation; JPMorgan said the melanoma indication was already priced in and that read-across to other cancers is critical for future value. The article highlights the debate over how large Moderna's oncology franchise can become.